Show simple item record

dc.contributor.authorKenfield, Stacey
dc.contributor.authorVan Blarigan, Erin L.
dc.contributor.authorDuPre, Natalie
dc.contributor.authorStampfer, Meir
dc.contributor.authorGiovannucci, Edward
dc.contributor.authorChan, June
dc.date.accessioned2019-09-05T17:04:11Z
dc.date.issued2015
dc.identifier.citationKenfield, S. A., E. L. Van Blarigan, N. DuPre, M. J. Stampfer, E. L. Giovannucci, and J. M. Chan. 2014. “Selenium Supplementation and Prostate Cancer Mortality.” JNCI Journal of the National Cancer Institute 107 (1): dju360-dju360. https://doi.org/10.1093/jnci/dju360.
dc.identifier.issn0027-8874
dc.identifier.issn0198-0157
dc.identifier.issn1460-2105
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:41292516*
dc.description.abstractFew studies have evaluated the relation between selenium supplementation after diagnosis and prostate cancer outcomes.We prospectively followed 4459 men initially diagnosed with nonmetastatic prostate cancer in the Health Professionals Follow-Up Study from 1988 through 2010 and examined whether selenium supplement use (from selenium-specific supplements and multivitamins) after diagnosis was associated with risk of biochemical recurrence, prostate cancer mortality, and, secondarily, cardiovascular disease mortality and overall mortality, using Cox proportional hazards models. All P values were from two-sided tests.We documented 965 deaths, 226 (23.4%) because of prostate cancer and 267 (27.7%) because of cardiovascular disease, during a median follow-up of 8.9 years. In the biochemical recurrence analysis, we documented 762 recurrences during a median follow-up of 7.8 years. Crude rates per 1000 person-years for prostate cancer death were 5.6 among selenium nonusers and 10.5 among men who consumed 140 or more mu g/day. Crude rates per 1000 person-years were 28.2 vs 23.5 for all-cause mortality and 28.4 vs 29.3 for biochemical recurrence, for nonuse vs highest-dose categories, respectively. In multivariable analyses, men who consumed 1 to 24 mu g/day, 25 to 139 mu g/day, and 140 or more mu g/day of supplemental selenium had a 1.18 (95% confidence interval [CI] = 0.73 to 1.91), 1.33 (95% CI = 0.77 to 2.30), and 2.60-fold (95% CI = 1.44 to 4.70) greater risk of prostate cancer mortality compared with nonusers, respectively, P (trend) = .001. There was no statistically significant association between selenium supplement use and biochemical recurrence, cardiovascular disease mortality, or overall mortality.Selenium supplementation of 140 or more mu g/day after diagnosis of nonmetastatic prostate cancer may increase risk of prostate cancer mortality. Caution is warranted regarding usage of such supplements among men with prostate cancer.
dc.language.isoen_US
dc.publisherOxford University Press
dash.licenseOAP
dc.titleSelenium Supplementation and Prostate Cancer Mortality
dc.typeJournal Article
dc.description.versionVersion of Record
dc.relation.journalJournal of the National Cancer Institute
dash.depositing.authorStampfer, Meir
dc.date.available2019-09-05T17:04:11Z
dash.workflow.comments1Science Serial ID 65013
dc.identifier.doi10.1093/jnci/dju360
dash.source.volume107;1
dash.contributor.affiliatedStampfer, Meir


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record